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Objectives. We tested whether mibefradil, a selective T-type
calcium channel blocking agent, could differentially inhibit experi-
mental ventricular arrhythmogenesis more than contractility dur-
ing acute regional ischemia and reperfusion compared with that
during L-channel blockade by verapamil.
Background. T-type calcium channels are found in nodal and
conduction tissue and in vascular smooth muscle, but in much
lower density in contractile myocardium. The potential role of
mibefradil in ventricular arrhythmogenesis remains unclear.
Methods. Mibefradil (Ro 40-5967, 1 mg/kg body weight intra-
venously [IV]) was given as a bolus 30 min before anterior
descending coronary artery ligation, followed by 2 mg/kg per h IV
during 20 min of ischemia and 25 min of reperfusion in open chest
pigs. In a second group, mibefradil was given in a dose twice as
high. A third group received verapamil (0.3 mg/kg IV), followed by
an infusion of 0.6 mg/kg per h.
Results. During the ischemic period, the low (clinically rele-
vant) dose of mibefradil prevented the fall of the ventricular
fibrillation threshold, without depressing the maximal rate of
pressure development of the left ventricle (LVmax dP/dt). This low
dose increased left ventricular blood flow, whereas peripheral
arterial pressure remained unchanged. The higher dose of both
mibefradil and verapamil was antiarrhythmic during ischemia, at
the cost of depressed contractile activity. During reperfusion, only
the higher dose of mibefradil and verapamil was antiarrhythmic
but both depressed contractile activity.
Conclusions. Mibefradil is antiarrhythmic, without inotropic
compromise. Speculatively, both T-type and L-type calcium chan-
nel blockade are involved in these effects.
(J Am Coll Cardiol 1998;32:268–74)
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Despite the continuous advances in the therapy of acute
myocardial infarction, sudden cardiac death largely caused by
ventricular arrhythmias remains important in the spectrum of
mortality in coronary heart disease (1). Such deaths typically
occur out of the hospital, outside the reach of thrombolytic
therapy. Because the incidence of ischemic heart disease is
likely to rise very substantially in the developing world early in
the next millennium (2), the global issue of sudden cardiac
death will become even more important.
Hypothetically, excess cytosolic calcium, as found in myo-
cardial ischemia, may play an important role in ischemic
ventricular arrhythmogenesis (3–6). From the therapeutic
point of view, there is no direct manner of modification of
cytosolic calcium in ischemic cells, but working from first
principles, two indirect pharmacologic procedures are possi-
ble: 1) Beta-adrenergic blockade should, by virtue of inhibition
of the formation of the second-messenger cyclic adenosine
monophosphate, lessen the probability of opening of the
calcium channel and hence be antiarrhythmic (4). 2) Calcium
channel blocking agents should achieve a similar effect by
directly binding to the calcium channel and lessening calcium
ion influx, which might be important in the initiation and
maintenance of ventricular fibrillation (7). These proposals
could have clinical relevance in postinfarction patients, as
shown by the decrease in sudden cardiac death when beta-
blockers are given prophylactically. Verapamil, a classic L-type
calcium channel blocker, reduced mortality only in a predeter-
mined subgroup without previous heart failure (8), suggesting
that its protection could be limited by its negative inotropic
action, as in the case of diltiazem (9). Experimentally, vera-
pamil prevents ventricular fibrillation in variety of models
(10–14), but at the cost of depressed myocardial contractile
function (14).
Mibefradil is a structurally novel calcium channel blocker
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from a new class of benzimidazolyl-substituted tetraline deriv-
atives (15,16). Mibefradil inhibits calcium influx through
T-type low voltage–activated calcium channels (17) ten times
more powerfully than influx through L-type channels (18).
T-type channels are present in very low densities in adult,
nondiseased ventricular tissue of various species (19,20), but
there appear to be no data on humans (21). In contrast,
T-channels are well expressed in pacemaker tissue, such as the
sinus node (22). A T-channel blocker such as mibefradil could
therefore be expected to decrease heart rate, with a lesser
effect on myocardial contractility. In addition mibefradil has
relatively weak L-channel blocking activity (23). Mibefradil
increased survival in a rat model of heart failure (24). When
given to patients with varying degrees of left ventricular
dysfunction, intravenous mibefradil is well tolerated. Ejection
fraction increases, but a decrease in the maximal first deriva-
tive of left ventricular pressure (LVmax dP/dt) occurs in some
patients with previous heart failure (25). Mibefradil has been
reported (26) to stimulate the release of endothelial-derived
relaxing factor. Mibefradil may also be relatively selective,
causing coronary versus peripheral vasodilation (27). We
therefore hypothesized that T-channel blockade by mibefradil
would be able to inhibit ischemic ventricular arrhythmias
without major depression of left ventricular contractile func-
tion.
We used the open chest porcine model, subject to acute
coronary artery ligation (CAL), followed by reperfusion. The
vulnerability of the heart to ventricular arrhythmias was mon-
itored by repetitive measurements of the ventricular fibrillation
threshold (VFT). The coronary and myocardial effects of
mibefradil were assessed by measurements of regional myo-
cardial blood flow and left ventricular contractile activity.
Comparisons were made with verapamil, using a dose known
to have antiarrhythmic effects in this model (14).
Methods
The ethics and research committee of the University of
Cape Town approved this study. Animals were handled in
accordance with the “Principles of Laboratory Animal Care”
of the National Society for Medical Research.
Study protocol. Male pigs (Large White crossed with Land-
race) weighing 27 to 30 kg were sedated by intramuscular
ketamine (10 mg/kg body weight). Anesthesia was induced by
intravenous thiopentone sodium (10 mg/kg). Approximately
5 min later, a bolus dose of 55 mg/kg of alpha-chloralose was
given, followed by a constant infusion of alpha-chloralose
(60 mg/kg) over ;60 min. In addition, the neuromuscular
blocker alcuronium chloride (0.02 mg/kg per min) was given as
an intravenous infusion for the duration of the experiment.
Animals were ventilated with room air; pO2 was controlled
between 95 and 105 mm Hg and pH between 7.43 and 7.48.
Standard limb lead electrocardiograms and arterial pressure
were monitored continuously. After a midsternal thoracotomy,
the left anterior descending coronary artery was dissected free
for ;5 mm at a point approximately one-half the distance from
its origin to its apical termination. It was abruptly ligated by
tightening thin polyvinyl tubing around a 2-cm length of rigid
tubing placed alongside the artery.
We measured the VFT by using the “train” method. An
electrical stimulus consisting of a train of 10 square wave
pulses was triggered by the R wave and distributed over 210 ms
during the T wave. The stimulus was passed between two
platinum electrodes sutured onto the anterior wall of the left
and right ventricles, 2.5 cm apart. The anode was placed across
the border of the expected ischemic zone in the left ventricle
and the cathode within the nonischemic zone of the right
ventricle. Pulses were generated using a Grass S88 stimulator.
The stimulus current was progressively increased in 2 mA steps
starting at 4 mA until ventricular fibrillation (VF) occurred
(28). The VFT was taken as the lowest current required to
produce VF. Care was taken not to use a longer train of pulses,
which may spill over into the refractory phase or late portion of
the T wave (29). A single VFT measurement required ;1 min.
Epicardial direct current shock was then applied usually within
4 s of the onset of VF and repeated if necessary. A return to
sinus rhythm could almost always be achieved within 30 s.
After 30 s, we alternated cardiac massage with defibrillation.
However, if defibrillation could not be accomplished within
90 s, the experiment was terminated. The VFT was measured
before CAL, 5 min after CAL and 10 min after reperfusion. In
addition to measurement of VFT, spontaneously occurring
ventricular arrhythmias were also monitored. Ventricular tachy-
cardia (VT) was defined as more than four consecutive uni-
form or multiform ventricular premature systoles. Runs of VF
or VT were considered terminated when they were followed by
at least three normally conducted sinus beats. Twenty minutes
after ligation, the ligature was released to reperfuse.
Left ventricular pressures and LVmax dP/dt were measured
using a Cardiomax computerized system (Columbus Instru-
ments). This system gives real-time displays of digital and
analog signals. Each variable is measured over at least three
consecutive cardiac cycles at a time when no arrhythmias are
evident. Each data point represents the mean of two readings.
Left ventricular blood flow was measured in the placebo
group, the low dose mibefradil group and the verapamil group
but not in the higher dose mibefradil group. Microspheres
were given before drug administration and CAL, 15 min after
CAL as well as 15 min after reperfusion using the sample
Abbreviations and Acronyms
CAL 5 coronary artery ligation
IV 5 intravenously
LVmax dP/dt 5 maximal rate of pressure development of the left
ventricle
LVSP 5 left ventricular systolic pressure
MAP 5 mean arterial pressure
VF 5 ventricular fibrillation
VFT 5 ventricular fibrillation threshold
VT 5 ventricular tachycardia
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reference method. The radionuclides utilized were
gadolinium-153, strontium-85 and tin-113 (New England Nu-
clear). The microspheres (mean size 15 mm) were prepared in
a 0.9% saline solution containing Tween-80 0.01% and admin-
istered according to previously described details and precau-
tions (30,31). Samples for gamma-spectrometry were dissected
from the midischemic and remote nonischemic zones of the
left ventricle.
Size of underperfused zone. At the end of the experiment,
the coronary artery was again ligated at the same site as before,
and the underperfused zone was delineated by injection of 5 ml
of patent blue 7.5% solution (May and Baker, UK) in saline
into the left atrium. The heart was then excised and arrested.
The size of this zone was expressed as a percent of total left
ventricular mass. When the underperfused zone was ,26% or
.34%, the results were not processed. This predetermined
exclusion criterion was used because of links between eventual
infarct size and arrhythmias (32,33).
Study groups. The prime aim of the present study was to
compare the effects of antiarrhythmic doses of mibefradil and
verapamil on contractile function.
Selection of doses. In a pilot study, mibefradil, 1 mg/kg
bolus followed by 2 mg/kg per h, was the lowest dose that
showed antiarrhythmic activity during ischemia. In a previous
study, verapamil at a clinically relevant dose (0.2 mg/kg) was
not antiarrhythmic in our model. A supraclinical dose of
0.6 mg/kg did show antiarrhythmic activity (14). We therefore
used a comparable supraclinical dose of verapamil in the
present study.
Placebo group (n 5 13). Each pig received 8 ml of saline
0.9% starting 30 min before CAL, followed by an infusion of
saline 0.9% for the remainder of the experiment.
Mibefradil, 1-mg/kg bolus followed by 2-mg/kg per h infusion
over 90 min (n 5 17): “low dose.” Each pig received mibefradil
(Hoffman-La Roche, Basel, Switzerland), 1 mg/kg intrave-
nously (IV) (powder dissolved in 8 ml of saline 0.9%), as a
bolus dose over 5 min starting at 30 min before CAL, followed
by 2 mg/kg per h IV for the remainder of the experiment.
Mibefradil, 2-mg/kg bolus followed by 4-mg/kg per h infusion
over 90 min (n 5 9): “higher dose.” Each pig received mibe-
fradil (Hoffman-La Roche), 2-mg/kg powder dissolved in 8 ml
of saline 0.9%), as a bolus dose over 5 min starting at 30 min
before CAL, followed by 4 mg/kg per h IV for the remainder
of the experiment.
Verapamil, 0.3-mg/kg bolus followed by 0.6-mg/kg per h
infusion over 90 min (n 5 11). Verapamil was obtained as a
5-mg/2-ml solution (Lennon, South Africa). Each pig received
verapamil (0.3-mg/kg bolus dose over 5 min) starting 30 min
before CAL, followed by an infusion of 0.6 mg/kg per hour IV
for the remainder of the experiment.
Statistical procedures. Results are expressed as mean
value 6 SEM. One-way analyses of variance and the Student t
test (two-tailed) were applied using paired analyses where
appropriate. The Fisher exact test was used for comparing the
incidence of spontaneous arrhythmias. The Bonferroni correc-
tion was applied to compensate for multiple comparisons (34).
A p value of ,0.05 was considered significant.
Results
A total of 50 pigs were used in the main study. Two pigs in
the mibefradil low dose group and two in the verapamil group
were excluded because the size of the underperfused zone was
,26% of total left ventricular mass. For various practical
reasons, all measurements could not always be made in all pigs.
Furthermore, certain procedures, for example, blood flow
measurements by costly radioactive microspheres, were con-
fined to a limited number of experiments. These two factors
explain the differing number of observations within each
group.
Spontaneous ventricular arrhythmias and VFT during
ischemia and reperfusion (Table 1). Ischemia. VFT before
CAL was 17.5 6 2.7 mA (placebo group), 21.7 6 2.5 mA
(mibefradil low dose group), 19.8 6 2.0 (mibefradil higher
dose group) and 18 6 2.1 mA (verapamil group). In the
placebo group, CAL caused a marked fall in VFT. In both
mibefradil groups as well as in the verapamil group, VFT was
maintained at higher levels than in the placebo group, indicat-
ing antiarrhythmic activity. The incidence of spontaneous
ventricular tachyarrhythmias was low in all groups.
Reperfusion. All runs of VT and VF occurred within the
first 10 min of reperfusion. At the time of the VFT measure-
ment, no rhythm disturbances were evident. Only the higher
dose of mibefradil and verapamil decreased the incidence of
VT and VF. Similarly, mibefradil (higher dose) and verapamil
Table 1. Occurrence of Spontaneous Tachyarrhythmias and
Ventricular Fibrillation Threshold During Ischemia and Reperfusion
VT VF
VFT (mA)
(mean 6 SEM)
Ischemia
Placebo 1/13 0/13 9.8 6 0.7
(n 5 13)
Mibefradil (1-mg/kg bolus followed
by 2-mg/kg per h infusion)
0/15 0/15 17.6 6 1.0*
(n 5 15)
Mibefradil (2-mg/kg bolus followed
by 4-mg/kg per h infusion)
1/9 0/9 17.6 6 1.9†
(n 5 9)
Verapamil (0.3-mg/kg bolus followed
by 0.6-mg/kg per h infusion)
0/9 0/9 16.2 6 0.8*
(n 5 8)
Reperfusion
Placebo 9/13 10/13 6.0 6 1.0
(n 5 11)
Mibefradil (1-mg/kg bolus followed
by 2-mg/kg per h infusion)
15/15 8/15 16.9 6 4.0
(n 5 15)
Mibefradil (2-mg/kg bolus followed
by 4-mg/kg per h infusion)
0/9† 1/9† 19.6 6 2.3*
(n 5 9)
Verapamil (0.3-mg/kg bolus followed
by 0.6-mg/kg per h infusion)
1/9‡ 1/9† 15.1 6 2.6†
(n 5 9)
*p , 0.001, †p , 0.02, ‡p , 0.05, versus placebo. VF 5 ventricular
fibrillation; VFT 5 ventricular fibrillation threshold; VT 5 ventricular tachy-
cardia.
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maintained VFT at higher levels than in the placebo group,
whereas the low dose of mibefradil did not.
Left ventricular pressures, arterial pressure and heart rate
(Table 2). CAL in the placebo group resulted in a decrease in
LVmax dP/dt, mean arterial pressure (MAP) and left ventric-
ular systolic pressure (LVSP). All three of these variables
remained low throughout the periods of ischemia and reper-
fusion. The administration of low dose mibefradil did not
change left ventricular or arterial pressures before CAL. All
values of LVmax dP/dt, LVSP and MAP during ischemia and
reperfusion in this group were comparable to those in the
placebo group. The higher dose of mibefradil as well as
verapamil markedly decreased LVmax dP/dt, LVSP and MAP
before CAL. These lower values were maintained during
ischemia and reperfusion. Heart rate was decreased during
ischemia and reperfusion in the higher dose mibefradil group
and during reperfusion in the verapamil group.
Regional left ventricular blood flow (Fig. 1). Left ventric-
ular blood flow before CAL in the placebo group was 185 6
18.6 ml/100 g per min, which did not differ from the predrug
and pre-CAL levels in the low dose mibefradil and verapamil
groups. Blood flow in each tissue sample during ischemia and
reperfusion was expressed as a percent of the predrug and
pre-CAL values for that specific sample. Blood flow was not
measured in the mibefradil higher dose group.
Blood flow during ischemic period. Midischemic zone: In all
three groups, blood flow fell to ,10% of pre-CAL values.
Nonischemic zone: Blood flow in the mibefradil low dose group
was higher than that in the placebo group (129 6 14% vs. 93 6
5%, p , 0.05). Blood flow in the verapamil group did not differ
from that in the placebo group.
Blood flow during reperfusion period. Midischemic zone:
There was a marked increase in blood flow in the mibefradil
low dose group (175 6 19% vs. 125 6 9% in the placebo group,
Table 2. Left Ventricular Pressures, Mean Arterial Pressure and Heart Rate
Before Drug
(mean 6 SEM)
Before CAL
(mean 6 SEM)
During Ischemia
(mean 6 SEM)
During Reperfusion
(mean 6 SEM)
Placebo (n 5 11–12)
LVSP — 105 6 5 86 6 5* 85 6 5*
LVmax dP/dt — 1,876 6 130 1,544 6 92† 1,310 6 55†
MAP — 93 6 3 75 6 4* 76 6 4*
HR — 117 6 5 125 6 5 125 6 6
Mibefradil (1-mg/kg bolus followed by
2-mg/kg per h infusion) (n 5 11–12)
LVSP 100 6 5 105 6 3 95 6 4 85 6 6*
LVmax dP/dt 2,003 6 68 1,884 6 85 1,645 6 51† 1,332 6 122†
MAP 93 6 3 86 6 3 83 6 4† 73 6 5†
HR 122 6 4 111 6 6 113 6 8 124 6 8
Mibefradil (2-mg/kg bolus followed by
4-mg/kg per h infusion) (n 5 6–9)
LVSP 111 6 8 80 6 7†‡§ 61 6 6†‡§ 62 6 6†‡§
LVmax dP/dt 1,844 6 96 1,429 6 102†\§ 766 6 86†\¶ 758 6 67†‡§
MAP 87 6 6 59 6 5†\¶ 45 6 4†\¶ 44 6 6†‡¶
HR 110 6 6 99 6 8 90 6 7*§ 86 6 9‡§
Verapamil (0.3-mg/kg bolus-followed by
0.6-mg/kg per h infusion) (n 5 6–9)
LVSP 97 6 5 87 6 5*‡§ 83 6 4† 83 6 4†
LVmax dP/dt 1,831 6 106 1,215 6 109†‡§ 1,195 6 100†‡§ 910 6 87†‡§
MAP 90 6 3 73 6 3†‡§ 65 6 2†‡§ 69 6 2†
HR 116 6 4 107 6 6 113 6 5 106 6 6§
*p , 0.05, †p , 0.02 versus before drug (or coronary artery ligation [CAL] in placebo group). ‡p , 0.05, \p , 0.001 versus mibefradil low dose. §p , 0.05, ¶p ,
0.001 versus placebo. HR 5 heart rate (beats/min); LVmax dP/dt 5 maximal rate of left ventricular pressure development (mm Hg/s); LVSP 5 left ventricular systolic
pressure (mm Hg); MAP 5 mean arterial pressure (mm Hg).
Figure 1. Regional left ventricular blood flow. During ischemia, low
dose mibefradil increased blood flow in the nonischemic (N I) zone.
During reperfusion, low dose mibefradil caused increases in blood flow
in both the ischemic (ISCH) and nonischemic zones, whereas vera-
pamil increased blood flow only in the nonischemic zone (blood flow
was not measured with higher dose of mibefradil). *p , 0.05, †p ,
0.01, both versus placebo. ‡p , 0.01 versus verapamil.
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p , 0.05). Blood flow in the verapamil group was lower than
that in the mibefradil group and did not differ from that in the
placebo group. Nonischemic zone: Both the mibefradil low
dose and verapamil increased blood flow (126 6 14% [p ,
0.05] and 135 6 12% [p , 0.01], respectively, vs. 89 6 5% in
the placebo group).
Size of underperfused zone. The zone sizes were 31 6 2%
(placebo group), 28 6 1% (mibefradil low dose group), 29 6
2% (mibefradil higher dose group), and 30 6 2% (verapamil
group).
Discussion
We tested the hypothesis that mibefradil, a proposed
selective T-type calcium channel blocker, could have antiar-
rhythmic activity without depressing contractile activity. Dur-
ing ischemia, the lower dose of mibefradil decreased the
vulnerability of the heart to VF, whereas changes in contractile
activity were comparable to those in the placebo group.
Because of the excellent bioavailability of mibefradil (.90%)
(23), intravenous doses are comparable to oral doses. Thus, the
lower intravenous dose used in our study is clinically relevant
because it more or less equals the oral antianginal dose of ;2
mg/kg in patients (35).
The finding that mibefradil reduced experimental arrhyth-
mias at a clinically relevant dose without depressing contractile
activity may render the agent useful in the setting of acute
myocardial infarction. In contrast, no dose of verapamil in our
model offered antiarrhythmic activity during ischemia without
a concomitant depression of left ventricular contractile activity.
In a previous study (14), a clinically relevant dose of verapamil
(0.2 mg/kg) was not antiarrhythmic. A higher (supraclinical)
dose of verapamil (0.6 mg/kg) was antiarrhythmic but at the
cost of depressing contractile activity (14). A comparable dose
of verapamil (0.3-mg/kg bolus followed by 0.6 mg/kg per h) in
the present study again depressed contractile activity.
Antiarrhythmic mechanisms of mibefradil during ische-
mia. A recent report (36) proposed that when intracellular
coupling is reduced, L-type calcium currents could cause
microreentry, thereby predisposing to arrhythmias in condi-
tions such as ischemia. L-type calcium current blockade should
therefore be particularly effective as antiarrhythmic agents
under these conditions. Moreover, mibefradil is a more effec-
tive blocker of L-type calcium channels in depolarized myo-
cardial cells than verapamil (37,38). Mibefradil may therefore
be particularly active in blocking L-channels in myocardial cells
that are depolarized by ischemia (39), with a greater effect as
cells become more depolarized. It is in such depolarized cells
that calcium overload may lead to severe ventricular arrhyth-
mias (3,40). We therefore speculate that mibefradil is “ische-
mia selective,” by virtue of these effects on L-channels of
depolarized cells. However, in the absence of the appropriate
electrophysiologic studies on isolated ventricular myocytes
subject to simulated ischemia, this proposal remains hypothet-
ical.
In addition to L-channel effects, we speculate that mibe-
fradil is ischemia selective through various effects mediated by
T-type calcium channel blockade: 1) Blockade of T-channels in
the coronary vasculature (41) may result in an increased blood
flow in the ischemic border zone, where reentrant arrhythmias
are believed to originate (39). During the ischemic period in
the present study, blood flow in the nonischemic zone was
increased by mibefradil, whereas that in the midischemic zone
remained unchanged. We did not measure blood flow in the
ischemic border zone. An increased blood flow in this zone
may have contributed to the antiarrhythmic activity of mibe-
fradil. 2) Blockade of T-type channels in Purkinje fibers (42) by
mibefradil might also help to inhibit arrhythmogenesis. 3)
Blockade of T-type calcium channels in cardiac pacemaker
cells may decrease heart rate and thereby limit calcium-
induced arrhythmias (5,43). However, the lower antiarrhyth-
mic dose of mibefradil used did not decrease heart rate in this
model. 4) Because T-type calcium channels play a small or no
role in excitation–contraction coupling (44), a relative absence
of a negative inotropic effect could be expected, as seen in the
present study.
Mibefradil and reperfusion arrhythmias. Cytosolic cal-
cium ion overload has been directly implicated in reperfusion
arrhythmias. Various L-type calcium channel blockers de-
creased reperfusion arrhythmias (40,45). In the present study
the L-type channel blocker verapamil reduced reperfusion
arrhythmias. Mibefradil, a weak L-type calcium channel
blocker, also decreased reperfusion arrhythmias but only at a
higher supraclinical dose. The failure of the low dose of
mibefradil to prevent reperfusion arrhythmias may in addition
be related to its effects on coronary blood flow. Mibefradil at
the low dose markedly increased blood flow in the reperfused
zone compared with the placebo and verapamil groups. Hypo-
thetically, a more rapid reintroduction of oxygen supply could
have enhanced the rate of generation of free radicals, resulting
in increased calcium oscillations (46) and early calcium-
dependent reperfusion ventricular tachyarrhythmias (45). We
did not measure blood flow in the group that received the
higher dose of mibefradil.
How relevant is VFT? In an earlier study (14), we reported
on a high incidence of spontaneous arrhythmias during isch-
emia in our pig-model. For reasons unknown, the incidence of
spontaneous arrhythmias in our model has decreased over
several years (47). However, VFT is a good index of the
vulnerability of the heart to arrhythmias, as we have shown
(48). We are therefore confident that results of the present
study offer a reliable basis for assessment of the antiarrhythmic
activity of verapamil versus mibefradil. With regard to reper-
fusion arrhythmias, there was good correlation in the present
study between the incidence of spontaneous ventricular tachy-
arrhythmias and the changes in VFT.
Measurement of VFT by the train method as an index of
the vulnerability of the heart to ventricular arrhythmias re-
quires special precautions. The train of stimuli, which is meant
to coincide with the vulnerable period of the cardiac cycle, may
spill over into the adjacent refractory zone and thereby fail to
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provoke VF (49). We took suitable precautions, as described in
Methods (29).
Mibefradil and left ventricular contractile activity. An
important observation in the present study is that the lower
(clinically relevant) dose of mibefradil, given during ischemia,
did not change contractile activity, as measured antiarrhythmi-
cally by LVmax dP/dt, compared with placebo group. When
myocardial ischemia was introduced in dogs with a previous
infarction (6), mibefradil in a comparable dose (1 mg/kg)
protected against VF induced by programmed electrical stim-
ulation, without adverse effects on LVmax dP/dt.
In contrast, in our model (14) a clinically relevant dose of
verapamil neither depressed contractile activity nor had anti-
arrhythmic effects. Antiarrhythmic effects were obtained with a
supraclinical dose of verapamil in the present study, but at the
cost of depression of contractile activity. These results suggest
that a mibefradil-like agent may be promising for further
assessment in acute myocardial infarction.
Conclusions. In the present study the T-type calcium chan-
nel blocker mibefradil, used in a clinically relevant dose, had
ischemic antiarrhythmic activity and increased coronary blood
flow, without depression of left ventricular contractile activity.
These data suggest, but do not prove, that T-channel blockade
could differentially influence arrhythmogenesis while main-
taining contractile activity. An additional antiarrhythmic prop-
erty of mibefradil may lie in its selective inhibition of
L-channels in depolarized tissue. Further testing is warranted
when pure T-type channel blockers become available.
These proposals may lead to a better understanding of the
full therapeutic spectrum of mibefradil. Although this drug has
recently been withdrawn from the market because of poten-
tially adverse drug interactions, the concept of combined
T-type and L-type calcium channel blockade remains novel
and of potential clinical interest.
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